Epithelial growth factor receptor status in primary and recurrent ovarian cancer

Stadlmann, Sylvia; Gueth, Uwe; Reiser, Ulrich; Diener, Pierre‐André; Zeimet, Alain G.; Wight, Edward; Mirlacher, Martina; Sauter, Guido; Mihatsch, Michael J.; Singer, Gad

doi:10.1038/modpathol.3800575

Cited by 69 publications

(61 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most published studies regarding HER1 have been performed on malignant tumor tissue and the vast majority of these studies measured HER1 expression using immunohistochemistry. HER1 overexpression has been reported in between 17-57% of the examined cases (4,5,(30)(31)(32)(33). Two studies have investigated the HER1 expression in benign ovarian tissue.…”

Section: Discussionmentioning

confidence: 99%

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Steffensen¹,

Waldstrøm²,

Andersen³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Steffensen¹,

Waldstrøm²,

Andersen³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

“…For FISH on biopsies, we used haematoxylin -eosin-stained tissue sections using our previously described standard FISH protocol (Stadlmann et al, 2006). No separate procedure for destaining was required.…”

Section: Specimen Pretreatment and Fish Assaymentioning

confidence: 99%

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

et al. 2007

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) gene mutations and increased copy numbers are considered as predictors of response to EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC). Lung cancer diagnosis is often based on cytology alone. However, almost all published data on EGFR gene analyses were obtained from biopsies. This study tested the feasibility of EGFR gene analyses on cytological specimens. Eighty-four cytological specimens from NSCLCs were prospectively analysed for EGFR gene mutation in exons 18 -21 and EGFR gene copy numbers were evaluated by fluorescence in situ hybridisation (FISH). A FISHpositive result was defined according to the criteria by Cappuzzo et al established for biopsies of NSCLCs. Fluorescence in situ hybridisation results of cytological specimens were compared to the FISH results on matching biopsies (n ¼ 33). Initial diagnosis of NSCLC was solely based on cytology in 37 out of 84 (44.0%) patients. Out of 80 NSCLCs, 6 (7.5%) showed EGFR gene mutations. Out of 67 cancers, 45 (67.2%) were FISH positive on cytological specimens. Comparison of FISH showed a FISH-positive result in 21 out of 33 (63.6%) cytological specimens but in only 8 out of 33 (24.2%) matched biopsies. Epidermal growth factor receptor gene analyses are well applicable to cytological specimens. The high FISH-positive rate of NSCLC on cytological specimens contrasts with the low rate on biopsies when previously suggested criteria are used. New criteria for a positive EGFR FISH status to predict response to therapy with EGFR-TKI need to be defined for cytological specimens.

show abstract

“…Activation of the EGFR signaling pathway has been linked with increased cell proliferation, angiogenesis, metastasis and decreased apoptosis. The literature has presented many reports that demonstrate the link between EGFR and some types of cancer, [15][16][17][18][19][20] which are generally associated with poor clinical outcome. Small molecules that inhibit the tyrosine kinase domain of EGFR have become critical new weapons in the treatment of some tumors, including non-small-cell lung carcinomas, 21 and they include gefitinib (Iressa, Astra Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals).…”

Section: Egfr In Gastrointestinal Stromal Tumormentioning

confidence: 99%

EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases

Lopes

Bacchi

2007

Modern Pathology

View full text Add to dashboard Cite

Gastrointestinal stromal tumor is the most common mesenchymal neoplasm of the gastrointestinal tract. Mutually exclusive KIT or platelet-derived growth factor receptor-a mutations are key events in gastrointestinal stromal tumor pathogenesis, and specific treatment targeting KIT/platelet-derived growth factor receptor-a activation is available. Epidermal growth factor receptor plays an important role in cancer biology and also constitutes a promising molecular target of therapy. Very few reports have been published in the literature about the relationship between gastrointestinal stromal tumor and epidermal growth factor receptor. The aim of this study was to investigate epidermal growth factor receptor immunohistochemical expression and epidermal growth factor receptor gene amplification in 82 consecutive gastrointestinal stromal tumor cases using tissue microarray technique. Hematoxylin-and eosin-stained sections and clinical information were reviewed, and expression of CD117 (KIT), CD34 and epidermal growth factor receptor was investigated by immunohistochemistry. Epidermal growth factor receptor gene copy number was determined using fluorescence in situ hybridization. Immunohistochemistry revealed that CD117 and CD34 were expressed in 96 and 57% of tumors, respectively. Variable epidermal growth factor receptor protein immunohistochemical overexpression was detected in 96% of gastrointestinal stromal tumor cases, but none of the 75 cases with represented tumor tissue cores and countable fluorescence signals exhibited epidermal growth factor receptor gene amplification by fluorescence in situ hybridization. These results show that there is no correlation between epidermal growth factor receptor protein overexpression by immunohistochemistry and epidermal growth factor receptor gene amplification by fluorescence in situ hybridization. Considering that the mechanisms of epidermal growth factor receptor protein overexpression are not well understood and the possibility that anti-epidermal growth factor receptor therapy may be beneficial for patients with gastrointestinal stromal tumor that overexpresses epidermal growth factor receptor, additional studies are encouraged. Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal (GI) tract. GIST generally occurs in older individuals (over the age of 50) and it can arise anywhere along the GI tract or even outside of it (extra-GI GIST), as in mesentery, omentum, retroperitoneum and pelvis. GISTs show peculiar immunohistochemical (KIT or CD117 and CD34 positivity) and molecular genetic findings, the latter characterized by mutually exclusive KIT or plateletderived growth factor receptor-a (PDGFRA) mutations. 1,2 The KIT and PDGFRA genes encode for similarly named transmembrane tyrosine kinase receptors that are involved in the development and maintenance of several cells. Activating (gain-offunction) mutations of KIT or PDGFRA permit the phosphorylation of the receptor tyrosine kinases, with activation of intracellular do...

show abstract

Epithelial growth factor receptor status in primary and recurrent ovarian cancer

Cited by 69 publications

References 14 publications

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers

EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases

Contact Info

Product

Resources

About